[go: up one dir, main page]

DK1326853T3 - Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7 - Google Patents

Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7

Info

Publication number
DK1326853T3
DK1326853T3 DK01969804T DK01969804T DK1326853T3 DK 1326853 T3 DK1326853 T3 DK 1326853T3 DK 01969804 T DK01969804 T DK 01969804T DK 01969804 T DK01969804 T DK 01969804T DK 1326853 T3 DK1326853 T3 DK 1326853T3
Authority
DK
Denmark
Prior art keywords
oxadiazoles
phosphodiesterase
inhibitors
thiadiazoles
novel
Prior art date
Application number
DK01969804T
Other languages
Danish (da)
English (en)
Inventor
Charles Andrianjara
Fabrice Vergne
Edwige Lorthiois
Pierre Ducrot
Patrick Bernardelli
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK1326853T3 publication Critical patent/DK1326853T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK01969804T 2000-10-02 2001-10-01 Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7 DK1326853T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (fr) 2000-10-02 2000-10-02 Thiadiazoles et leur utilisation comme inhibiteurs de phophodiestérase-7

Publications (1)

Publication Number Publication Date
DK1326853T3 true DK1326853T3 (da) 2005-12-12

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01969804T DK1326853T3 (da) 2000-10-02 2001-10-01 Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7

Country Status (43)

Country Link
US (1) US7122565B2 (fr)
EP (2) EP1193261A1 (fr)
JP (1) JP4177098B2 (fr)
KR (1) KR100614158B1 (fr)
CN (1) CN1639141A (fr)
AP (1) AP1541A (fr)
AR (1) AR035347A1 (fr)
AT (1) ATE304003T1 (fr)
AU (2) AU2001289945B2 (fr)
BG (1) BG107654A (fr)
BR (1) BR0114391A (fr)
CA (1) CA2424279A1 (fr)
CZ (1) CZ2003857A3 (fr)
DE (1) DE60113283T2 (fr)
DK (1) DK1326853T3 (fr)
DZ (1) DZ3440A1 (fr)
EA (1) EA007179B1 (fr)
EC (1) ECSP034534A (fr)
EE (1) EE200300134A (fr)
ES (1) ES2247166T3 (fr)
GE (1) GEP20053459B (fr)
GT (1) GT200100196A (fr)
HN (1) HN2001000217A (fr)
HR (1) HRP20030247A2 (fr)
HU (1) HUP0301248A3 (fr)
IL (1) IL155122A0 (fr)
IS (1) IS6759A (fr)
MA (1) MA25916A1 (fr)
MX (1) MXPA03002839A (fr)
NO (1) NO20031482D0 (fr)
NZ (1) NZ524852A (fr)
OA (1) OA12518A (fr)
PA (1) PA8529501A1 (fr)
PE (1) PE20020419A1 (fr)
PL (1) PL366332A1 (fr)
PT (1) PT1326853E (fr)
SI (1) SI1326853T1 (fr)
SK (1) SK3812003A3 (fr)
SV (1) SV2003000633A (fr)
TN (1) TNSN01139A1 (fr)
WO (1) WO2002028847A1 (fr)
YU (1) YU24503A (fr)
ZA (1) ZA200302346B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044235A1 (fr) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Procedes de diagnostic de maladies associees a la phosphodiesterase 7a1 (pde7a1) humaine et moyens therapeutiques correspondants
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
PL1775298T3 (pl) 2004-07-01 2013-08-30 Daiichi Sankyo Co Ltd Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
WO2007047978A2 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
EP1942879A1 (fr) 2005-10-31 2008-07-16 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EP2139475B1 (fr) 2007-03-27 2014-12-17 Omeros Corporation Inhibiteurs de PDE7 pour le traitement de troubles du mouvement
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US20120115849A1 (en) 2010-11-08 2012-05-10 Demopulos Gregory A Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
JP6855466B2 (ja) * 2015-06-12 2021-04-07 オリゾン ジェノミックス ソシエダッド アノニマ Lsd1阻害剤に関連するバイオマーカーおよびそれらの使用
HUE066069T2 (hu) 2016-12-16 2024-07-28 Baxter Int Mikafungin készítmények
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
EP4572765A1 (fr) 2022-08-18 2025-06-25 Mitodicure GmbH Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (fr)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
DE69909592T4 (de) * 1998-02-17 2005-03-24 Roche Diagnostics Gmbh Verwendung von thiadiazolo[4,3-a]pyridine derivaten

Also Published As

Publication number Publication date
ES2247166T3 (es) 2006-03-01
HN2001000217A (es) 2002-06-13
US7122565B2 (en) 2006-10-17
DZ3440A1 (fr) 2002-04-11
AP2003002764A0 (en) 2003-03-31
YU24503A (sh) 2006-03-03
SV2003000633A (es) 2003-04-03
GT200100196A (es) 2002-07-18
EA007179B1 (ru) 2006-08-25
CZ2003857A3 (cs) 2004-02-18
PA8529501A1 (es) 2003-06-30
GEP20053459B (en) 2005-02-25
WO2002028847A1 (fr) 2002-04-11
EP1326853B1 (fr) 2005-09-07
IS6759A (is) 2003-03-27
BR0114391A (pt) 2003-06-24
IL155122A0 (en) 2003-10-31
CA2424279A1 (fr) 2002-04-11
DE60113283T2 (de) 2006-06-08
EE200300134A (et) 2003-08-15
US20030045557A1 (en) 2003-03-06
DE60113283D1 (de) 2005-10-13
PE20020419A1 (es) 2002-07-18
OA12518A (en) 2006-05-29
TNSN01139A1 (en) 2005-11-10
KR100614158B1 (ko) 2006-08-21
PL366332A1 (en) 2005-01-24
PT1326853E (pt) 2005-11-30
ATE304003T1 (de) 2005-09-15
HUP0301248A2 (hu) 2003-10-28
EA200300333A1 (ru) 2003-10-30
JP4177098B2 (ja) 2008-11-05
EP1326853A1 (fr) 2003-07-16
ECSP034534A (es) 2003-07-25
AP1541A (en) 2006-01-11
MXPA03002839A (es) 2004-09-10
SK3812003A3 (en) 2004-05-04
NO20031482L (no) 2003-04-01
ZA200302346B (en) 2004-08-04
AU2001289945B2 (en) 2005-12-22
HRP20030247A2 (en) 2005-04-30
NO20031482D0 (no) 2003-04-01
AU8994501A (en) 2002-04-15
AR035347A1 (es) 2004-05-12
SI1326853T1 (sl) 2005-12-31
CN1639141A (zh) 2005-07-13
EP1193261A1 (fr) 2002-04-03
JP2004510769A (ja) 2004-04-08
BG107654A (bg) 2003-12-31
KR20030068542A (ko) 2003-08-21
NZ524852A (en) 2004-09-24
MA25916A1 (fr) 2003-10-01
HUP0301248A3 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
DK1326853T3 (da) Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
DK1223933T3 (da) 5-leddet derivater af heterocyklusser og deres anvendelse som monoaminoxidaseinhibitorer
NO20014135L (no) Nye sulfonamidforbindelser og deres anvendelse
NO20013452L (no) Benzoheterocykler og deres anvendelse som MEK-inhibitorer
NO20005265L (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20024742L (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20031065D0 (no) Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser
NO20032645L (no) Heterocykliske sulfonamidinhibitorer av <beta>- amyloidproduksjonen
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
ID30590A (id) Celana sekali pakai jenis-celana pendek
ATE258918T1 (de) Kristallform alpha des perindopril-tert- butylaminsalzes
DK1227088T3 (da) Krystallinsk base af citalopram og hydrochlorid- eller hydrobromidsaltet deraf
IS7344A (is) Stýrð efnasmíði síprasídóns og samsetninga af því
NO20030298L (no) Nye heteroarylderivater og deres anvendelse som farmasöytiske midler
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
DK1339679T3 (da) 3-Aroylindolderivater og deres anvendelse som agonister af CB2-receptorer
EE9900053A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
ATE281181T1 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
NO20023956D0 (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
NO20022007L (no) Krystaller av et oksyiminoalkansyrederivat og deres anvendelse som antidiabetika
NO20035399D0 (no) Pyrrolidinoksadiazol- og tiadiazolderivater
NO20021007L (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner og deres anvendelse som lipasehemmere
NO20030813L (no) Bifenylderivater og deres anvendelse som integrininhibitorer